Nkarta Inc (NKTX)

[jondoeuk]

I hope for the combo CAR-T plus CAR-NK cell trial, they use an NKG2D CAR (+/- another CAR) NK cell product as these have been observed to shift macrophages towards an M1 phenotype [1], reduce Tregs [2], are antiangiogenic [3], and could induce a host derived CD4+ and CD8+ T-cell response [4].

Refs:
1 https://www.jimmunol.org/content/188/12/6389
2 https://www.jimmunol.org/content/183/11/6939.abstract
3 https://www.jimmunol.org/content/190/5/2455.short
4 https://www.nature.com/articles/gt2010174